Passage Bio, Inc.
PASG
NASDAQ·Healthcare·Biotechnology·Mkt cap $14.9M
$4.65
▼ -2.11%
P/E
—
Mkt Cap
$14.9M
52-Wk Range
$3.29–$20.00
52-Week Range
$3.29 - $20.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 32.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Value
Valuation data unavailable
Momentum
Weak
-15.0% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying PASG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$2.44 vs -$2.27 consensus (-7.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.5%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
5 analysts · 20% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
20%
Hold
80%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Jun 10, 2026
vs Industry
How PASG stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.